Drug Pharmacologya | Doses | Route | Strain/Species | Sex | ICSS Procedureb | Drug Effectc | Dependent Measure | Reference | ||
---|---|---|---|---|---|---|---|---|---|---|
Drug Name | Selectivity | Structure | Parameter | |||||||
mg/kg | ||||||||||
Cocaine | DA/NE/5HT | 0.63–10 | s.c. | Wistar rat | Male | Free operant | Facilitation | ↑rate | Wauquier and Niemergeers, 1974 | |
Cocaine | DA/NE/5HT | 1–10 | i.p. | Fischer rat | Male | Discrete trial | Amplitude | Facilitation | ↓CIT | Esposito et al., 1978 |
Cocaine | DA/NE/5HT | 1–10 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Facilitation | ↑rate | Negus et al., 2012a |
Cocaine | DA/NE/5HT | 1.25–10 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Facilitation | ↓θ0 | Tomasiewicz et al., 2008 |
Cocaine | DA/NE/5HT | 1–30 | i.p. | C57Bl6/J mouse | Male | Hybrid | Frequency | Facilitation | ↓θ0 | Fish et al., 2010 |
Cocaine | DA/NE/5HT | 1–30 | i.p. | DBA mouse | Male | Hybrid | Frequency | Facilitation | ↓θ0 | Fish et al., 2010 |
MDPV | DA/NE>5HT | 0.32–3.2 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Facilitation | ↑rate | Bonano et al., 2014 |
MDPV | DA/NE>5HT | 0.1–2.0 | i.p. | Sprague-Dawley rat | Male | Discrete trial | Amplitude | Facilitation | ↓CIT | Watterson et al., 2014 |
GBR 12935 | DA>NE/5HT | 1.0–10 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Facilitation | ↑rate | K. Freitas and S. S. Negus, unpublished |
RTI-113 | DA>NE/5HT | 0.32–3.2 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Facilitation | ↑rate | Rosenberg et al., 2013 |
Methylphenidate | DA/NE>5HT | 0.1–10 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Facilitation | ↑rate | K. Freitas and S. S. Negus, unpublished |
Buproprion | DA/NE>5HT | 3.2–32 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Facilitation | ↑rate | Rosenberg et al., 2013 |
RTI-112 | DA/NE/5HT | 0.1–1.0 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Facilitation | ↑rate | Rosenberg et al., 2013 |
Amitifadine | DA/NE/5HT | 1–10 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Mixed | ↑↓rate | L. L. Miller and S. S. Negus, unpublished |
Citalopram | DA/NE<5HT | 3.2–32 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Depression | ↓rate | Rosenberg et al., 2013 |
Clomipramine | DA<NE/5HT | 3.2–32 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Depression | ↓rate | Rosenberg et al., 2013 |
Fluoxetine | DA/NE<5HT | 1.0–10 | i.p. | Sprague-Dawley rat | Male | Free operant | Depression | ↓rate | Katz and Carroll, 1977 | |
Fluoxetine | DA/NE<5HT | 2.5-20 | i.p. | Wistar rat | Male | Discrete trial | Amplitude | Depression | ↑CIT | Lee and Kornetsky, 1998 |
Nisoxetine | DA/5HT<NE | 1–10 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Depression | ↓rate | Rosenberg et al., 2013 |
Nortryptaline | DA<5HT<NE | 1–10 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Depression | ↓rate | Rosenberg et al., 2013 |
Rate, response rate; CIT, current-intensity threshold; θ0, theta-0 threshold.
↵a Selectivity for monoamine uptake inhibition.
↵b First column indicates structure of experimental session (see text for details). Second column indicates stimulation parameter under manipulation across trials.
↵c Most prominent drug effect on ICSS.